Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAP-AD
NCT04784416Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Apr 2021
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 2, randomised trial in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Repeatable Battery for the Assessment of Neuropsychological Status Update Total Scale Index at 8 weeks. Started Apr 2021; status: completed.
02
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04784416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784416.